Q1 · MEDICINE
Article
Author: Watanabe, Takashi ; Shirai, Fumiyuki ; Watanabe, Hirofumi ; Honma, Teruki ; Sato, Shin ; Shitara, Eiki ; Mazaki, Yui ; Shirouzu, Mikako ; Muramatsu, Yukiko ; Umehara, Takashi ; Yuki, Hitomi ; Okue, Masayuki ; Seimiya, Hiroyuki ; Koda, Yasuko ; Hirama, Chizuko ; Kano, Yuko ; Yoshimoto, Nobuko ; Kitamura, Kouichi ; Niwa, Hideaki ; Yoshida, Minoru ; Yoshida, Haruka ; Tsumura, Takeshi ; Washizuka, Kenichi ; Yashiroda, Yoko ; Mizutani, Anna ; Onuki, Tetsuo ; Chikada, Tsubasa ; Koyama, Hiroo ; Abe, Masako ; Fukami, Takehiro
The canonical WNT pathway plays an important role in cancer pathogenesis. Inhibition of poly(ADP-ribose) polymerase catalytic activity of the tankyrases (TNKS/TNKS2) has been reported to reduce the Wnt/β-catenin signal by preventing poly ADP-ribosylation-dependent degradation of AXIN, a negative regulator of Wnt/β-catenin signaling. With the goal of investigating the effects of tankyrase and Wnt pathway inhibition on tumor growth, we set out to find small-molecule inhibitors of TNKS/TNKS2 with suitable drug-like properties. Starting from 1a, a high-throughput screening hit, the spiroindoline derivative 40c (RK-287107) was discovered as a potent TNKS/TNKS2 inhibitor with >7000-fold selectivity against the PARP1 enzyme, which inhibits WNT-responsive TCF reporter activity and proliferation of human colorectal cancer cell line COLO-320DM. RK-287107 also demonstrated dose-dependent tumor growth inhibition in a mouse xenograft model. These observations suggest that RK-287107 is a promising lead compound for the development of novel tankyrase inhibitors as anticancer agents.